Clinical trials: Demyelinating Disorder
Multiple Sclerosis, Spasticity
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
A study to compare the change in cognitive performance and psychological status of patients with spasticity due to Multiple Sclerosis when treated with Sativex or placebo, added to existing anti-spasticity therapy over a period…
- Trial name
- NCT01964547
- Testing
- Sativex
- Where
- Czechia
- Volunteers
- 121 people
- Sponsor
- Jazz Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
- Trial name
- NCT00317941
- Testing
- Betaferon/Betaseron, Rebif
- Where
- 59 sites in France
- Volunteers
- 220 people
- Sponsor
- Bayer
Multiple Sclerosis
Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis
The objective of this study is to validate a different version of the 6 minutes Walk Test (6minWT), the 6minWT on 6 meters, instead of the 30 meters.
- Trial name
- VR6minWT6 (NCT04228328)
- Testing
- The 6-minutes Walk Test
- Where
- Switzerland
- Volunteers
- 21 people
- Sponsor
- Haute Ecole de Santé Vaud
Multiple Sclerosis
Long-Term Effects of Torso-Weighting
The goal of this pilot study is to test the protocol for investigating the longer-term effects of torso weighting on physical activity, number of falls, and muscle activation (when muscles turn on and off and how intensely) in…
- Trial name
- TWPS (NCT02743312)
- Testing
- Torso Weights, Fitbit Flex
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- San Francisco State University
Secondary Progressive Multiple Sclerosis
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
This is a Phase 3b, multicenter, international study conducted in 2 parts. Upon completion of the placebo-controlled period (Part 1), participants will have the option of enrolling in a 2-year open-label extension (Part 2).
- Trial name
- ASCEND in SPMS (NCT01416181)
- Testing
- natalizumab
- Where
- 161 sites in United States, Belgium and 15 more
- Volunteers
- 889 people
- Sponsor
- Biogen
Multiple Sclerosis
Lipoic Acid for Progressive Multiple Sclerosis (MS)
The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.
- Trial name
- LAPMS (NCT03161028)
- Testing
- Lipoic acid
- Where
- 11 sites in United States, Canada
- Volunteers
- 115 people
- Sponsor
- VA Office of Research and Development
Relapsing-remitting Multiple Sclerosis
Study of Evobrutinib in Participants With RMS
The study was to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Interferon-beta-1a (Avonex®), once a week intramuscularly in participants with Relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT04032171
- Testing
- Evobrutinib, Avonex®
- Where
- 2 sites in United States, Germany
- Volunteers
- 1 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
The purpose of the study is to assess the influence of pantoprazole on the pharmacokinetic profile of cladribine, especially in terms of extent of absorption of cladribine since pH-modifying drug may potentially affect the…
- Trial name
- NCT00938366
- Testing
- Cladribine, Pantoprazole
- Volunteers
- 18 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
The purpose of this study is (1) to determine if rituximab induction therapy followed by glatiramer acetate (GA) is substantially superior to placebo rituximab induction followed by GA for the treatment of clinically isolated…
- Trial name
- GATEWAYII (NCT01569451)
- Testing
- Rituximab, Glatiramer Acetate
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS.
- Trial name
- OLYMPUS (NCT00087529)
- Testing
- rituximab
- Volunteers
- 439 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
Promoting Physical Activity Behavior in Persons With Multiple Sclerosis
The purpose of this research study is to evaluate whether tailored print material can promote physical activity and exercise, and subsequently improve quality of life and fitness levels among people with multiple sclerosis (MS).
- Trial name
- NCT01572207
- Testing
- Immediate exercise, Delayed exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Case Western Reserve University
Multiple Sclerosis, Relapsing-remitting
Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis
This is a research study. The investigators are inviting participants to participate in this research study between the ages of 18-45, who have stable Relapsing-Remitting Multiple Sclerosis (RRMS), are able to walk 25 ft…
- Trial name
- NCT02687919
- Testing
- Modified Paleo diet
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Amanda Irish
Multiple Sclerosis
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
The purpose of this study is to investigate the safety and efficacy of a lower dose of dalfampridine extended release tablets compared to the currently approved dose in improving walking in Multiple Sclerosis (MS) patients.
- Trial name
- NCT01328379
- Testing
- Dalfampridine-ER 5mg, Dalfampridine-ER 10mg
- Where
- 70 sites in United States
- Volunteers
- 430 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis
Cannabis for Spasticity in Multiple Sclerosis
The purpose of this study is to learn if the use of inhaled cannabis (marijuana) and oral cannabinoid (dronabinol, Marinol or THC, which is an active ingredient of marijuana) is safe and effective in reducing the symptoms of…
- Trial name
- NCT00682929
- Testing
- Inhaled Cannabis, Oral THC
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of California, Davis
Multiple Sclerosis
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week…
- Trial name
- DreaMS (NCT01226745)
- Testing
- ONO-4641
- Where
- 70 sites in United States, Belgium and 9 more
- Volunteers
- 340 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or…
- Trial name
- OMS115102 (NCT00640328)
- Testing
- Ofatumumab 100, Ofatumumab 300, Ofatumumab 700
- Volunteers
- 38 people
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS)
This is a pragmatic, single-blinded randomized trial of improving adherence to dietary interventions in patients with MS who are receiving monthly natalizumab infusions.
- Trial name
- NCT02846558
- Testing
- Frequent Patient Interaction, Timing Restriction, LoseIt! Smartphone Application
- Volunteers
- 54 people
- Sponsor
- Johns Hopkins University
Relapsing Remitting Multiple Sclerosis
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
This is a study evaluating the effect on brain volume of daily glatiramer acetate (GA) and add-on pulse steroids.
- Trial name
- ASSERT (NCT00203047)
- Testing
- Glatiramer Acetate, Prednisone
- Volunteers
- 414 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue
The overarching aim is to assess the role of microglial activation and norepinephrine transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission Tomography (PET) radiotracers, [F-18]PBR06 and…
- Trial name
- NCT04144257
- Testing
- [F-18]PBR06, [C-11]Methylreboxetine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Relapsing-remitting Multiple Sclerosis
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with RRMS aged between 10 and < 18 years over a flexible duration.
- Trial name
- Operetta 2 (NCT05123703)
- Testing
- Ocrelizumab, Fingolimod
- Where
- 71 sites in United States, Argentina and 23 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche